Search

everythinglearnresearchcommunity

for

Search:↓

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Cimetidine is not a first-choice treatment for female hair loss, and there's no consistently successful treatment for this condition in men or normal hormone level women.

An arthritis drug helped a person with severe hair loss regrow their hair.

The new cocrystal KET-PABA is a more effective and safe anti-inflammatory treatment for skin conditions in mice.

New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.

Rituximab improved her dermatomyositis better than usual treatments.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

Finasteride and GIZh-72 reduce inflammation, with GIZh-72 being more effective.

Upadacitinib effectively treats psoriasis and lichen planus together.

Ixekizumab effectively treats generalized pustular psoriasis.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.

Ixekizumab effectively treated severe psoriasis and hair loss in a patient.

Two women experienced temporary hair loss and other side effects from imiquimod treatment for cervical issues, which stopped after ending the treatment.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

Biosimilars lower costs but don't significantly improve access.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

A drug called cimetidine can help treat hair loss in women by blocking androgen receptors. However, it's not the first choice and needs more research.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.